Skip to main content
SpringerLink
Log in

Clear Cell Sarcoma

  • Chapter
  • First Online:
Rare Sarcomas

  • 346 Accesses

Abstract

Clear cell sarcoma (CCS) is an aggressive, rare soft-tissue sarcoma, initially described by Dr. Enzinger. The tumor has a propensity to involve the tendons and aponeuroses of distal extremities of relatively young individuals. This sarcoma is characterized by multiple local recurrences with late metastases, frequent lymph node involvement and a poor prognosis. CCS is also referred as a malignant melanoma of soft parts because of its melanocytic features. Molecular genetic studies have shown cytogenetic rearrangements resulting in a EWSR1-ATF1 fusion gene specific of CCS. Poor prognostic factors include mitotic index ≥10, presence of necrosis, primary tumor size ≥5 cm, presence of metastases at diagnosis and trunk localization. Wide surgical excision remains the only curative treatment for localized cases. Sentinel node biopsy has been reported in CCS but the benefit of this procedure still needs further investigation. The treatment of advanced, inoperable CCS remains indeed a challenge due to the lack of an established systemic standard of treatment. CCS tends to be resistant both to chemotherapy and to radiation therapy. Objective tumor responses have been observed upon tyrosine kinase inhibitors (sorafenib and sunitinib). A recent phase II trial demonstrated that crizotinib provided a clinical benefit, with 69.2% of CCS cases achieving disease control for a median of 131 days. Anecdotal reports have included a complete response to interferon alpha, stable disease for 6–24 months in two patients after ipilimumab treatment, and a partial and a complete clinical response in two patients after pembrolizumab.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CCS:

Clear cell sarcoma

EFS:

Event free survival

HGF:

Hepatocyte growth factor

ILP:

Isolated limb perfusion

MITF:

Microphtalmia-associated transcription factor

OS:

Overall survival

PFS:

Progression free survival

SLNB:

Sentinel lymph node biopsy

References

  1. Enzinger FM. Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer. 1965;18:1163–74.

    Google Scholar 

  2. Blazer DG, Lazar AJ, Xing Y, Askew RL, Feig BW, Pisters PWT, et al. Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the surveillance, epidemiology, and end results registry. Cancer. 2009;115(13):2971–9.

    Google Scholar 

  3. Zagars GK, Ballo MT, Pisters PWT, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97(10):2530–43.

    Google Scholar 

  4. Chung EB, Enzinger FM. Malignant melanoma of soft parts. A reassessment of clear cell sarcoma. Am J Surg Pathol. 1983;7(5):405–13.

    Google Scholar 

  5. Sara AS, Evans HL, Benjamin RS. Malignant melanoma of soft parts (clear cell sarcoma). A study of 17 cases, with emphasis on prognostic factors. Cancer. 1990;65(2):367–74.

    Google Scholar 

  6. Lucas DR, Nascimento AG, Sim FH. Clear cell sarcoma of soft tissues. Mayo Clinic experience with 35 cases. Am J Surg Pathol. 1992;16(12):1197–204.

    Google Scholar 

  7. Finley JW, Hanypsiak B, McGrath B, Kraybill W, Gibbs JF. Clear cell sarcoma: the Roswell Park experience. J Surg Oncol. 2001;77(1):16–20.

    Google Scholar 

  8. Kuiper DR, Hoekstra HJ, Veth RPH, Wobbes T. The management of clear cell sarcoma. Eur J Surg Oncol. 2003;29(7):568–70.

    Google Scholar 

  9. Coindre J-M, Hostein I, Terrier P, Bouvier-Labit C, Collin F, Michels J-J, et al. Diagnosis of clear cell sarcoma by real-time reverse transcriptase-polymerase chain reaction analysis of paraffin embedded tissues: clinicopathologic and molecular analysis of 44 patients from the French sarcoma group. Cancer. 2006;107(5):1055–64.

    Google Scholar 

  10. Kawai A, Hosono A, Nakayama R, Matsumine A, Matsumoto S, Ueda T, et al. Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer. 2007;109(1):109–16.

    Google Scholar 

  11. Clark MA, Johnson MB, Thway K, Fisher C, Thomas JM, Hayes AJ. Clear cell sarcoma (melanoma of soft parts): The Royal Marsden Hospital experience. Eur J Surg Oncol. 2008;34(7):800–4.

    Google Scholar 

  12. Hisaoka M, Ishida T, Kuo T-T, Matsuyama A, Imamura T, Nishida K, et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. Am J Surg Pathol. 2008;32(3):452–60.

    Google Scholar 

  13. Hocar O, Le Cesne A, Berissi S, Terrier P, Bonvalot S, Vanel D, et al. Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract. 2012;2012:1–8.

    Google Scholar 

  14. Bianchi G, Charoenlap C, Cocchi S, Rani N, Campagnoni S, Righi A, et al. Clear cell sarcoma of soft tissue: a retrospective review and analysis of 31 cases treated at Istituto Ortopedico Rizzoli. Eur J Surg Oncol. 2014;40(5):505–10.

    Google Scholar 

  15. Brennan MF, Antonescu CR, Maki RG. Clear cell sarcoma/melanoma of soft parts. In: Management of soft tissue sarcoma. New York: Springer; 2013. p. 267–73. https://doi.org/10.1007/978-1-4614-5004-7_18.

    Google Scholar 

  16. Bridge JA, Sreekantaiah C, Neff JR, Sandberg AA. Cytogenetic findings in clear cell sarcoma of tendons and aponeuroses. Malignant melanoma of soft parts. Cancer Genet Cytogenet. 1991;52(1):101–6.

    Google Scholar 

  17. Panagopoulos I, Mertens F, Dêbiec-Rychter M, Isaksson M, Limon J, Kardas I, et al. Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses. Int J Cancer. 2002;99(4):560–7.

    Google Scholar 

  18. Graadt van Roggen JF, Mooi WJ, Hogendoorn PC. Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) and cutaneous melanoma: exploring the histogenetic relationship between these two clinicopathological entities. J Pathol. 1998;186(1):3–7.

    Google Scholar 

  19. Langezaal SM, Graadt van Roggen JF, Cleton-Jansen AM, Baelde JJ, Hogendoorn PC. Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts). Br J Cancer. 2001;84(4):535–8.

    Google Scholar 

  20. Reeves BR, Fletcher CDM, Gusterson BA. Translocation t (12; 22)(q13; q13) is a nonrandom rearrangement in clear cell sarcoma. Cancer Genet Cytogenet. 1992;64(2):101–3.

    Google Scholar 

  21. Wang W-L, Mayordomo E, Zhang W, Hernandez VS, Tuvin D, Garcia L, et al. Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). Mod Pathol. 2009;22(9):1201–9.

    Google Scholar 

  22. Zucman J, Delattre O, Desmaze C, Epstein AL, Stenman G, Speleman F, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet. 1993;4(4):341–5.

    Google Scholar 

  23. Speleman F, Delattre O, Peter M, Hauben E, Van Roy N, Van Marck E. Malignant melanoma of the soft parts (clear-cell sarcoma): confirmation of EWS and ATF-1 gene fusion caused by a t(12;22) translocation. Mod Pathol. 1997;10(5):496–9.

    Google Scholar 

  24. Speleman F, Colpaert C, Goovaerts G, Leroy JG, Van Marck E. Malignant melanoma of soft parts. Further cytogenetic characterization. Cancer Genet Cytogenet. 1992;60(2):176–9.

    Google Scholar 

  25. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: clear cell sarcoma (malignant melanoma of soft parts). Cancer Genet Cytogenet. 2001;130(1):1–7.

    Google Scholar 

  26. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217(1):72–7.

    Google Scholar 

  27. Eckardt JJ, Pritchard DJ, Soule EH. Clear cell sarcoma. A clinicopathologic study of 27 cases. Cancer. 1983;52(8):1482–8.

    Google Scholar 

  28. Stockman DL, Miettinen M, Suster S, Spagnolo D, Dominguez-Malagon H, Hornick JL, et al. Malignant gastrointestinal neuroectodermal tumor: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumors of the gastrointestinal tract. Am J Surg Pathol. 2012;36(6):857–68.

    Google Scholar 

  29. Malchau SS, Hayden J, Hornicek F, Mankin HJ. Clear cell sarcoma of soft tissues. J Surg Oncol. 2007;95(6):519–22.

    Google Scholar 

  30. Deenik W, Mooi WJ, Rutgers EJ, Peterse JL, Hart AA, Kroon BB. Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 30 cases. Cancer. 1999;86(6):969–75.

    Google Scholar 

  31. Hantschke M, Mentzel T, Rütten A, Palmedo G, Calonje E, Lazar AJ, et al. Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma. Am J Surg Pathol. 2010;34(2):216–22.

    Google Scholar 

  32. Kothaj P, Turcan I, Marko L, Cunderlík P, Fukal J, Okapec S. [Malignant melanoma of soft parts (clear cell sarcoma)—a rare case of multiorgan localization]. Rozhl V Chir Mesicnik Ceskoslovenske Chir Spolecnosti. 1998;77(7):328–33.

    Google Scholar 

  33. Tsuneyoshi M, Enjoji M, Kubo T. Clear cell sarcoma of tendons and aponeuroses: a comparative study of 13 cases with a provisional subgrouping into the melanotic and synovial types. Cancer. 1978;42(1):243–52.

    Google Scholar 

  34. Yamada K, Ohno T, Aoki H, Semi K, Watanabe A, Moritake H, et al. EWS/ATF1 expression induces sarcomas from neural crest-derived cells in mice. J Clin Invest. 2013;123(2):600–10.

    Google Scholar 

  35. Pavlidis NA, Fisher C, Wiltshaw E. Clear-cell sarcoma of tendons and aponeuroses: a clinicopathologic study. Presentation of six additional cases with review of the literature. Cancer. 1984;54(7):1412–7.

    Google Scholar 

  36. Segal NH, Pavlidis P, Noble WS, Antonescu CR, Viale A, Wesley UV, et al. Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol. 2003;21(9):1775–81.

    Google Scholar 

  37. Mackey SL, Hebel J, Cobb MW. Melanoma of the soft parts (clear cell sarcoma): a case report and review of the literature. J Am Acad Dermatol. 1998;38(5):815–9.

    Google Scholar 

  38. Bridge JA, Borek DA, Neff JR, Huntrakoon M. Chromosomal abnormalities in clear cell sarcoma. Implications for histogenesis. Am J Clin Pathol. 1990;93(1):26–31.

    Google Scholar 

  39. Mukai M, Torikata C, Iri H, Mikata A, Kawai T, Hanaoka H, et al. Histogenesis of clear cell sarcoma of tendons and aponeuroses. An electron-microscopic, biochemical, enzyme histochemical, and immunohistochemical study. Am J Pathol. 1984;114(2):264–72.

    Google Scholar 

  40. Epstein AL, Martin AO, Kempson R. Use of a newly established human cell line (SU-CCS-1) to demonstrate the relationship of clear cell sarcoma to malignant melanoma. Cancer Res. 1984;44(3):1265–74.

    Google Scholar 

  41. Straessler KM, Jones KB, Hu H, Jin H, van de Rijn M, Capecchi MR. Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation state impacts tumor characteristics. Cancer Cell. 2013;23(2):215–27.

    Google Scholar 

  42. Meis-Kindblom JM. Clear cell sarcoma of tendons and aponeuroses: a historical perspective and tribute to the man behind the entity. Adv Anat Pathol. 2006;13(6):286–92.

    Google Scholar 

  43. Jones RL, Constantinidou A, Thway K, Ashley S, Scurr M, Al-Muderis O, et al. Chemotherapy in clear cell sarcoma. Med Oncol. 2011;28(3):859–63.

    Google Scholar 

  44. Weingrad DN, Rosenberg SA. Early lymphatic spread of osteogenic and soft-tissue sarcomas. Surgery. 1978;84(2):231–40.

    Google Scholar 

  45. Riad S, Griffin AM, Liberman B, Blackstein ME, Catton CN, Kandel RA, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop. 2004;426:129–34.

    Google Scholar 

  46. Mazeron JJ, Suit HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer. 1987;60(8):1800–8.

    Google Scholar 

  47. Daigeler A, Kuhnen C, Moritz R, Stricker I, Goertz O, Tilkorn D, et al. Lymph node metastases in soft tissue sarcomas: a single center analysis of 1,597 patients. Langenbecks Arch Surg Dtsch Ges Für Chir. 2009;394(2):321–9.

    Google Scholar 

  48. Vezeridis MP, Moore R, Karakousis CP. Metastatic patterns in soft-tissue sarcomas. Arch Surg. 1983;118(8):915–8.

    Google Scholar 

  49. Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM, Brennan MF. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 1999;85(2):389–95.

    Google Scholar 

  50. Takahira T, Oda Y, Tamiya S, Yamamoto H, Kawaguchi K, Kobayashi C, et al. Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma. Cancer Sci. 2004;95(8):651–5.

    Google Scholar 

  51. Park BM, Jin SA, Choi YD, Shin SH, Jung ST, Lee JB, et al. Two cases of clear cell sarcoma with different clinical and genetic features: cutaneous type with BRAF mutation and subcutaneous type with KIT mutation. Br J Dermatol. 2013;169(6):1346–52.

    Google Scholar 

  52. Granville L, Hicks J, Popek E, Dishop M, Tatevian N, Lopez-Terrada D. Visceral clear cell sarcoma of soft tissue with confirmation by EWS-ATF1 fusion detection. Ultrastruct Pathol. 2006;30(1):111–8.

    Google Scholar 

  53. Raskin GA, Pozharisski KM, Iyevleva AG, Rikov IV, Orlova RV, Imyanitov EN. Unusual clinical presentation of gastrointestinal clear cell sarcoma. Gastrointest Tumors. 2015;2(2):83–8.

    Google Scholar 

  54. Zambrano E, Reyes-Mugica M, Franchi A, Rosai J. An osteoclast-rich tumor of the gastrointestinal tract with features resembling clear cell sarcoma of soft parts: reports of 6 cases of a GIST simulator. Int J Surg Pathol. 2003;11(2):75–81.

    Google Scholar 

  55. Kosemehmetoglu K, Folpe AL. Clear cell sarcoma of tendons and aponeuroses, and osteoclast-rich tumour of the gastrointestinal tract with features resembling clear cell sarcoma of soft parts: a review and update. J Clin Pathol. 2010;63(5):416–23.

    Google Scholar 

  56. Pauwels P, Debiec-Rychter M, Sciot R, Vlasveld T, den Butter B, Hagemeijer A, et al. Clear cell sarcoma of the stomach. Histopathology. 2002;41(6):526–30.

    Google Scholar 

  57. Fukuda T, Kakihara T, Baba K, Yamaki T, Yamaguchi T, Suzuki T. Clear cell sarcoma arising in the transverse colon. Pathol Int. 2000;50(5):412–6.

    Google Scholar 

  58. Ekfors TO, Kujari H, Isomäki M. Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) in the duodenum: the first visceral case. Histopathology. 1993;22(3):255–9.

    Google Scholar 

  59. Comin CE, Novelli L, Tornaboni D, Messerini L. Clear cell sarcoma of the ileum: report of a case and review of literature. Virchows Arch Int J Pathol. 2007;451(4):839–45.

    Google Scholar 

  60. Antonescu CR, Nafa K, Segal NH, Dal Cin P, Ladanyi M. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res. 2006;12(18):5356–62.

    Google Scholar 

  61. Parasuraman S, Rao BN, Bodner S, Cain A, Pratt CB, Merchant TE, et al. Clear cell sarcoma of soft tissues in children and young adults: the St. Jude Children’s Research Hospital experience. Pediatr Hematol Oncol. 1999;16(6):539–44.

    Google Scholar 

  62. Ferrari A, Casanova M, Bisogno G, Mattke A, Meazza C, Gandola L, et al. Clear cell sarcoma of tendons and aponeuroses in pediatric patients: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group. Cancer. 2002;94(12):3269–76.

    Google Scholar 

  63. Kindblom LG, Lodding P, Angervall L. Clear-cell sarcoma of tendons and aponeuroses. An immunohistochemical and electron microscopic analysis indicating neural crest origin. Virchows Arch A Pathol Anat Histopathol. 1983;401(1):109–28.

    Google Scholar 

  64. Jo VY, Fletcher CDM. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014;46(2):95–104.

    Google Scholar 

  65. Travis JA, Bridge JA. Significance of both numerical and structural chromosomal abnormalities in clear cell sarcoma. Cancer Genet Cytogenet. 1992;64(2):104–6.

    Google Scholar 

  66. Covinsky M, Gong S, Rajaram V, Perry A, Pfeifer J. EWS-ATF1 fusion transcripts in gastrointestinal tumors previously diagnosed as malignant melanoma. Hum Pathol. 2005;36(1):74–81.

    Google Scholar 

  67. Stenman G, Kindblom LG, Angervall L. Reciprocal translocation t(12;22)(q13;q13) in clear-cell sarcoma of tendons and aponeuroses. Genes Chromosomes Cancer. 1992;4(2):122–7.

    Google Scholar 

  68. Persengiev SP, Green MR. The role of ATF/CREB family members in cell growth, survival and apoptosis. Apoptosis Int J Program Cell Death. 2003;8(3):225–8.

    Google Scholar 

  69. Antonescu CR, Tschernyavsky SJ, Woodruff JM, Jungbluth AA, Brennan MF, Ladanyi M. Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. J Mol Diagn. 2002;4(1):44–52.

    Google Scholar 

  70. Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, et al. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell. 2006;9(6):473–84.

    Google Scholar 

  71. Limon J, Debiec-Rychter M, Nedoszytko B, Liberski PP, Babińska M, Szadowska A. Aberrations of chromosome 22 and polysomy of chromosome 8 as non-random changes in clear cell sarcoma. Cancer Genet Cytogenet. 1994;72(2):141–5.

    Google Scholar 

  72. Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, et al. Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. Genes Chromosomes Cancer. 2012;51(2):111–26.

    Google Scholar 

  73. Garcia JJ, Kramer MJ, O’Donnell RJ, Horvai AE. Mismatch repair protein expression and microsatellite instability: a comparison of clear cell sarcoma of soft parts and metastatic melanoma. Mod Pathol. 2006;19(7):950–7.

    Google Scholar 

  74. Song JS, Choi J, Kim JH, Jang SJ, Cho K-J. Diagnostic utility of EWS break-apart fluorescence in situ hybridization in distinguishing between non-cutaneous melanoma and clear cell sarcoma: EWS rearrangement in clear cell sarcoma. Pathol Int. 2010;60(9):608–13.

    Google Scholar 

  75. Isoda H, Kuroda M, Saitoh M, Asakura T, Akai M, Ikeda K, et al. MR findings of clear cell sarcoma: two case reports. Clin Imaging. 2003;27(4):229–32.

    Google Scholar 

  76. Al-Nakshabandi NA, Munk PL. Radiology for the surgeon. Musculoskeletal case 38. Diagnosis: clear cell sarcoma of the foot. Can J Surg J Can Chir. 2007;50(1):58–9.

    Google Scholar 

  77. De Beuckeleer LH, De Schepper AM, Vandevenne JE, Bloem JL, Davies AM, Oudkerk M, et al. MR imaging of clear cell sarcoma (malignant melanoma of the soft parts): a multicenter correlative MRI-pathology study of 21 cases and literature review. Skelet Radiol. 2000;29(4):187–95.

    Google Scholar 

  78. Hourani M, Khoury N, Mourany B, Shabb NS. MR appearance of clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts): radiologic-pathologic correlation. Skelet Radiol. 2005;34(9):543–6.

    Google Scholar 

  79. Wetzel LH, Levine E. Soft-tissue tumors of the foot: value of MR imaging for specific diagnosis. AJR Am J Roentgenol. 1990;155(5):1025–30.

    Google Scholar 

  80. Fuglø HM, Jørgensen SM, Loft A, Hovgaard D, Petersen MM. The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging. 2012;39(9):1416–24.

    Google Scholar 

  81. Ergül N, Aydın M. FDG PET/CT findings in rare sarcomas. Rev Esp Med Nucl E Imagen Mol. 2013;32(5):324–7.

    Google Scholar 

  82. Nguyen BD, Roarke MC, Ram PC. PET monitoring of clear cell sarcoma of tendons and aponeuroses. Clin Nucl Med. 2007;32(5):415–7.

    Google Scholar 

  83. Terazawa K, Otsuka H, Morita N, Yamashita K, Nishitani H. Clear-cell sarcoma of the small intestine detected by FDG-PET/CT during comprehensive examination of an inflammatory reaction. J Med Investig. 2009;56(1-2):70–5.

    Google Scholar 

  84. Fujimoto T, Andoh T, Sudo T, Fujita I, Imabori M, Moritake H, et al. Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies. Appl Radiat Isot. 2011;69(12):1713–6.

    Google Scholar 

  85. Ipach I, Mittag F, Kopp H-G, Kunze B, Wolf P, Kluba T. Clear-cell sarcoma of the soft tissue - a rare diagnosis with a fatal outcome: clear-cell sarcoma of the soft tissue. Eur J Cancer Care. 2012;21(3):412–20.

    Google Scholar 

  86. Stoeckle E, Gardet H, Coindre J-M, Kantor G, Bonichon F, Milbéo Y, et al. Prospective evaluation of quality of surgery in soft tissue sarcoma. Eur J Surg Oncol. 2006;32(10):1242–8.

    Google Scholar 

  87. Andreou D, Boldt H, Werner M, Hamann C, Pink D, Tunn P-U. Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread—results of a large prospective trial. Ann Oncol. 2013;24(5):1400–5.

    Google Scholar 

  88. Behranwala KA, A’Hern R, Omar A-M, Thomas JM. Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol. 2004;11(7):714–9.

    Google Scholar 

  89. Al-Refaie WB, Ali MW, Chu DZ, Paz IB, Blair SL. Clear cell sarcoma in the era of sentinel lymph node mapping. J Surg Oncol. 2004;87(3):126–9.

    Google Scholar 

  90. van Akkooi ACJ, Verhoef C, van Geel AN, Kliffen M, Eggermont AMM, de Wilt JHW. Sentinel node biopsy for clear cell sarcoma. Eur J Surg Oncol. 2006;32(9):996–9.

    Google Scholar 

  91. Nishida Y, Yamada Y, Tsukushi S, Shibata S, Ishiguro N. Sentinel lymph node biopsy reveals a positive popliteal node in clear cell sarcoma. Anticancer Res. 2005;25(6C):4413–6.

    Google Scholar 

  92. Wright S, Armeson K, Hill EG, Streck C, Leddy L, Cole D, et al. The role of sentinel lymph node biopsy in select sarcoma patients: a meta-analysis. Am J Surg. 2012;204(4):428–33.

    Google Scholar 

  93. Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol. 2007;14(2):553–9.

    Google Scholar 

  94. Kinnaert E, Morandini R, Simon S, Hill HZ, Ghanem G, Van Houtte P. The degree of pigmentation modulates the radiosensitivity of human melanoma cells. Radiat Res. 2000;154(5):497–502.

    Google Scholar 

  95. Marcrom S, De Los Santos JF, Conry RM. Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy. Clin Sarcoma Res. 2017;7:14.

    Google Scholar 

  96. Andoh T, Fujimoto T, Suzuki M, Sudo T, Sakurai Y, Tanaka H, et al. Boron neutron capture therapy (BNCT) as a new approach for clear cell sarcoma (CCS) treatment: trial using a lung metastasis model of CCS. Appl Radiat Isot. 2015;106:195–201.

    Google Scholar 

  97. Andoh T, Fujimoto T, Sudo T, Suzuki M, Sakurai Y, Sakuma T, et al. Boron neutron capture therapy as new treatment for clear cell sarcoma: trial on different animal model. Appl Radiat Isot. 2014;88:59–63.

    Google Scholar 

  98. Takeuchi A, Tsuchiya H, Yamamoto N, Hayashi K, Yamauchi K, Kawahara M, et al. Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res. 2007;27(5B):3489–95.

    Google Scholar 

  99. Karita M, Tsuchiya H, Yamamoto N, Shirai T, Hayashi K, Nishida H. Caffeine-potentiated chemotherapy for clear cell sarcoma: a report of five cases. Int J Clin Oncol. 2013;18(1):33–7.

    Google Scholar 

  100. Tomita K, Tsuchiya H. Caffeine enhancement of the effect of anticancer agents on human sarcoma cells. Jpn J Cancer Res. 1989;80(1):83–8.

    Google Scholar 

  101. Takeda A, Tsuchiya H, Tajino T, Kikuchi S-I. An experimental study on the therapeutic effect of consecutive low-dose cisplatin with caffeine in sarcoma-bearing mice. Anticancer Res. 2005;25(4):2777–84.

    Google Scholar 

  102. Tazzari M, Palassini E, Vergani B, Villa A, Rini F, Negri T, et al. Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. BMC Cancer. 2015;15:58.

    Google Scholar 

  103. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011;22(7):1682–90.

    Google Scholar 

  104. Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, et al. Tumor response to sunitinib malate observed in clear-cell sarcoma. Ann Oncol. 2010;21(5):1130–1.

    Google Scholar 

  105. Mir O, Boudou-Rouquette P, Larousserie F, Babinet A, Dumaine V, Anract P, et al. Objective response to sorafenib in advanced clear-cell sarcoma. Ann Oncol. 2012;23(3):807–9.

    Google Scholar 

  106. Outani H, Tanaka T, Wakamatsu T, Imura Y, Hamada K, Araki N, et al. Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS. BMC Cancer. 2014;14:455.

    Google Scholar 

  107. Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 2010;70(2):639–45.

    Google Scholar 

  108. Wagner AJ, Goldberg JM, DuBois SG, Choy E, Rosen L, Pappo A, et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012;118(23):5894–902.

    Google Scholar 

  109. Schöffski P, Wozniak A, Casali PG, Rutkowski P, Blay J-Y, Lindner LH, et al. Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 “CREATE”. Ann Oncol. 2017;28(12):3000–8.

    Google Scholar 

  110. Lauro S, Bordin F, Trasatti L, Lanzetta G, Della Rocca C, Frati L. Concurrent chemoimmunotherapy in metastatic clear cell sarcoma: a case report. Tumori. 1999;85(6):512–4.

    Google Scholar 

  111. Steger GG, Wrba F, Mader R, Schlappack O, Dittrich C, Rainer H. Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses. Eur J Cancer. 1991;27(3):254–6.

    Google Scholar 

  112. Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22(6):1364–70.

    Google Scholar 

  113. Forrest S, Church A, Schmidt B, et al. Metastatic clear cell sarcoma in a 6-year old mimicking metastatic melanoma and successfully treated with checkpoint inhibitors. CTOS Ann Meet. 2015.

    Google Scholar 

  114. Protsenko SA, Semionova AI, Komarov YI, Aleksakhina SN, Ivantsov AO, Iyevleva AG, et al. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Investig New Drugs. 2015;33(5):1136–43.

    Google Scholar 

  115. Liu S, Cheng H, Kwan W, Lubieniecka JM, Nielsen TO. Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Mol Cancer Ther. 2008;7(6):1751–61.

    Google Scholar 

  116. Schaefer K-L, Brachwitz K, Braun Y, Diallo R, Wai DH, Zahn S, et al. Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. Neoplasia. 2006;8(7):613–22.

    Google Scholar 

  117. Schaefer K-L, Brachwitz K, Wai DH, Braun Y, Diallo R, Korsching E, et al. Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. Cancer Res. 2004;64(10):3395–405.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, ICM Montpellier Cancer Institute, Montpellier, France

    Nelly Firmin

  2. Department of Pathology, Cochin Hospital, AP-HP, Paris, France

    Frédérique Larousserie

  3. Department of Pediatric Oncology, Oscar Lambret Center, Lille, France

    Anne-Sophie Defachelles

  4. Department of Medical Oncology, Cochin Hospital, AP-HP, Paris, France

    Pascaline Boudou-Rouquette

Authors
  1. Nelly Firmin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frédérique Larousserie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne-Sophie Defachelles
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pascaline Boudou-Rouquette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nelly Firmin .

Editor information

Editors and Affiliations

  1. IUCT Oncopole, Institut Claudius Regaud, Toulouse, France

    Christine Chevreau

  2. Institut Bergonié, Bordeaux, France

    Antoine Italiano

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Firmin, N., Larousserie, F., Defachelles, AS., Boudou-Rouquette, P. (2020). Clear Cell Sarcoma. In: Chevreau, C., Italiano, A. (eds) Rare Sarcomas. Springer, Cham. https://doi.org/10.1007/978-3-030-24697-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-24697-6_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-24696-9

  • Online ISBN: 978-3-030-24697-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation